# A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)

> **NCT07450053** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Idiopathic Short Stature

## Interventions

- **DRUG:** GenSci134 Injection
- **DRUG:** Recombinant Human Growth Hormone Injection(Norditropin® FlexPro®)

## Key facts

- **NCT ID:** NCT07450053
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-06
- **Primary completion:** 2028-07-18
- **Final completion:** 2028-12-31
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07450053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07450053, "A Study (Phase 1b/2) of GenSci134 in Children With Idiopathic Short Stature (ISS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07450053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*